Meet anicells @ the annual bio.be event in Brussels

Meet us at the annual bio.be event on September 26 in Brussels. Theme of the event: ATMPs! Discover how Belgium is paving the way in Europe and how it can further develop into a center of excellence for these innovative therapies. We are pleased that we are invited to this event to explain our vision […]

Congratulation to the alumni of the first Summer School Program on GMP for Advanced Therapies

GMP Advanced Therapies

From 13 to 15 September, the first ‘Summer School Program on GMP for Advanced Therapies’ was organized in the Science Park University of Antwerp. This program offers students ‘Laboratory Technology and Chemistry’ students from the ‘AP Hogeschool Antwerpen‘ and the ‘Karel de Grote Hogeschool‘ the unique opportunity to truly experience working in a GMP environment, […]

Check the SME BioForum Report on ATMPs

Check out the great SME BioForum report from EuropaBio – The European Association for Bioindustries, dedicated to Advanced Therapies (ATMPs). This report brings together the voice of biotech SMEs and results in a list of recommendations needed to create a sustainable ecosystem for ATMPs in Europe. We are pleased that our QC/QA Manager, Sam Vanleene, […]

End of Summer After Work Drink

End of Summer

For most of us, summer holidays are over. Recharged and full of energy we go back to work. Cheers from our ‘End of Summer After Work Drink’! Do you want to be part of our team? Just send a message to Nathalie@anicells.com. We are always looking for great talents. Published on 08/09/2022

Anicells werft aan/is hiring

Hiring

Cel- en gentherapieën zijn de behandelingen van de toekomst en dit voor verschillende ziekten. Naast de ontwikkeling van deze therapieën moeten deze ook geproduceerd worden, vaak volledig gepersonaliseerd voor één enkele patiënt. Deze gespecialiseerd productie is de expertise van anicells. Het is dan ook niet verwonderlijk dat veel ontwikkelaars de weg naar anicells vinden. Hierdoor […]

Prof. Anguille, hematologist at UZA, talks about the future of cell therapy

Dr Anguille

Today, cell therapy is at the forefront of development. Using living cells from a patient or healthy donor as medicine has the potential to improve many patients’ lives. Learn from Prof. Sébastien Anguille, hematologist at the Antwerp University Hospital, how he is successfully using cell therapy to treat patients with blood cancers, such as leukemia. […]

Join anicells @ Advanced Therapies in London

Advanced Therapies

Anicells will attend the ‘Advanced Therapies’ conference on 24 and 25 May in London. We look forward to meeting ATMP players from across the world and partnering with them to bring these innovative therapies to market and to patients faster. Are you looking for a partner to produce your ATMP? Contact us and we’ll meet […]

Anicells produceert CAR-T cellen voor patiënt met lymfeklierkanker

Anicells was op nationale televisie! Aanleiding was een bijzondere prestatie van het anicells team. Als eerste in Vlaanderen produceerden zij CAR-T cellen voor de behandeling van een patiënt met lymfeklierkanker. Deze behandeling, die onderdeel is van een studie, werd uitgevoerd door het team van prof. dr. Sébastien Anguille in het UZA in Antwerpen. Zijn onderzoeksgroep […]

Knowledge for Growth 2022 was a great success

Yesterday the Life Sciences community came together in Ghent at the Knowledge for Growth conference, organized by flanders.bio.  Our CEO, Nathalie Cools, who moderated the roundtable discussion on innovations in CAR-T manufacturing, thanks the panel members, Thibault Jonckheere (Exothera), Tessa Kerre (UZ Gent), Ief Leroy (VILS), Bie Van de Vloet (Janssen Belgium) and Maarten Zandvliet […]

Join anicells at ‘Knowledge for Growth 2022’

Knowledge for Growth is live again! On May 18 and 19, the biotech community will come together in Ghent and anicells will be there for sure. At the request of Flanders.bio, the at.las network is organizing a debate on CAR-T therapies. Nathalie Cools, CEO of anicells and co-founder of at.las, will expertly moderate this debate […]